Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more
Mycenax Biotech (4726) - Net Assets
Latest net assets as of September 2025: NT$1.64 Billion TWD
Based on the latest financial reports, Mycenax Biotech (4726) has net assets worth NT$1.64 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.33 Billion) and total liabilities (NT$1.69 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.64 Billion |
| % of Total Assets | 49.34% |
| Annual Growth Rate | 8.49% |
| 5-Year Change | 67.0% |
| 10-Year Change | N/A |
| Growth Volatility | 33.3 |
Mycenax Biotech - Net Assets Trend (2017–2024)
This chart illustrates how Mycenax Biotech's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mycenax Biotech (2017–2024)
The table below shows the annual net assets of Mycenax Biotech from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.02 Billion | -17.31% |
| 2023-12-31 | NT$2.45 Billion | -21.20% |
| 2022-12-31 | NT$3.11 Billion | +62.88% |
| 2021-12-31 | NT$1.91 Billion | +57.36% |
| 2020-12-31 | NT$1.21 Billion | +9.96% |
| 2019-12-31 | NT$1.10 Billion | +21.49% |
| 2018-12-31 | NT$907.01 Million | -20.71% |
| 2017-12-31 | NT$1.14 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mycenax Biotech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27743800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$2.49 Billion | 123.07% |
| Total Equity | NT$2.02 Billion | 100.00% |
Mycenax Biotech Competitors by Market Cap
The table below lists competitors of Mycenax Biotech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inclusio Sca
BR:INCLU
|
$115.77 Million |
|
Arvind SmartSpaces Limited
NSE:ARVSMART
|
$115.80 Million |
|
Exicon Co. Ltd
KQ:092870
|
$115.81 Million |
|
Wendell Industrial Co. Ltd
TWO:6761
|
$115.82 Million |
|
ChargePoint Holdings Inc
NYSE:CHPT
|
$115.66 Million |
|
Wam Strategic Value Ltd
AU:WAR
|
$115.62 Million |
|
TREVI-FIN. INDUSTR.
F:TV92
|
$115.61 Million |
|
OceanPact Serviços Marítimos S.A
SA:OPCT3
|
$115.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mycenax Biotech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,447,192,000 to 2,023,479,000, a change of -423,713,000 (-17.3%).
- Net loss of 467,125,000 reduced equity.
- New share issuances of 35,968,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-467.12 Million | -23.09% |
| Share Issuances | NT$35.97 Million | +1.78% |
| Other Changes | NT$7.44 Million | +0.37% |
| Total Change | NT$- | -17.31% |
Book Value vs Market Value Analysis
This analysis compares Mycenax Biotech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.15x to 3.36x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$10.41 | NT$32.80 | x |
| 2018-12-31 | NT$8.25 | NT$32.80 | x |
| 2019-12-31 | NT$10.02 | NT$32.80 | x |
| 2020-12-31 | NT$9.45 | NT$32.80 | x |
| 2021-12-31 | NT$12.43 | NT$32.80 | x |
| 2022-12-31 | NT$15.13 | NT$32.80 | x |
| 2023-12-31 | NT$11.90 | NT$32.80 | x |
| 2024-12-31 | NT$9.77 | NT$32.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mycenax Biotech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -68.30%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.66x
- Recent ROE (-23.09%) is below the historical average (-16.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -16.47% | -59.12% | 0.24x | 1.15x | NT$-302.76 Million |
| 2018 | -30.26% | -129.80% | 0.19x | 1.23x | NT$-365.13 Million |
| 2019 | -19.80% | -55.82% | 0.28x | 1.28x | NT$-328.37 Million |
| 2020 | 2.55% | 4.65% | 0.38x | 1.45x | NT$-90.22 Million |
| 2021 | -4.71% | -11.61% | 0.25x | 1.65x | NT$-280.52 Million |
| 2022 | -14.61% | -61.95% | 0.16x | 1.43x | NT$-764.19 Million |
| 2023 | -27.90% | -104.63% | 0.17x | 1.54x | NT$-927.57 Million |
| 2024 | -23.09% | -68.30% | 0.20x | 1.66x | NT$-669.47 Million |
Industry Comparison
This section compares Mycenax Biotech's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,107,525,400
- Average return on equity (ROE) among peers: 2.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mycenax Biotech (4726) | NT$1.64 Billion | -16.47% | 1.03x | $115.74 Million |
| Synbio Tech Inc. (1295) | $942.97 Million | 12.01% | 1.00x | $21.72K |
| Apex Biotechnology Corp (1733) | $842.42 Million | 19.18% | 0.14x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $875.36 Million | 7.09% | 0.89x | $129.07 Million |
| Panion & BF Biotech Inc (1760) | $278.86 Million | -14.55% | 2.31x | $123.88 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.02 Billion | 5.81% | 0.71x | $42.95 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.16 Billion | 13.75% | 0.60x | $45.13 Million |
| Level Biotechnology (3118) | $498.78 Million | 7.80% | 0.36x | $22.63 Million |
| GenMont Biotech Inc (3164) | $861.62 Million | 3.30% | 0.66x | $31.27 Million |
| Medigen Biotechnology (3176) | $3.18 Billion | -14.68% | 0.53x | $100.57 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $56.40 Million |